Current perspective on infections and mitigation strategies in primary systemic vasculitis

• Published in: Current rheumatology reports 2024-08, Vol.26 (8), p.279-289
• Main Authors: Tumba, Manuel Carpio, Silva, Raisa Lomanto, Arevalo, Ana B., Sattui, Sebastian E.
• Format: Article
• Language: English
• Subjects: Medicine; Medicine & Public Health; Review; Rheumatology; Topical Collection on Vasculitis
• ISSN: 1523-3774; 1534-6307; 1534-6307
• DOI: 10.1007/s11926-024-01149-6

Purpose of Review The purpose of this review is to summarize and evaluate most recent evidence on the epidemiology of infections and associated risk factors in patients with primary systemic vasculitides (PSV), as well as discuss mitigation strategies including the risk of antibiotic prophylaxis. Recent Findings Infections remain one of the leading causes of mortality in patients with PSV, with rates of severe infection ranging from 16 to 40% in different cohorts. Older age, frailty, renal and pulmonary involvement, and higher burden of comorbidities have been recognized as important patient-associated risk factors. Treatments including higher cumulative doses of glucocorticoids are associated with an increased risk of infections, and recent studies show the potential benefit of interventions such as reduced-dose glucocorticoid regimens. Existing mitigation strategies include screening, vaccination, and infection prophylaxis. The latter remains particularly important for Pneumocystis jirovecii pneumonia; however, the benefit-risk ratio seems to be less clear outside of induction phase (i.e., high dose of glucocorticoids) and optimal treatment duration remains less clear. Summary Patients with PSV are at increased risk of infections, due to disease itself, comorbidities, and treatment side effects. Awareness of the timing and types of infection, as well as mitigation strategies are imperative to ensure treatment success and survival for patients.